TB-500 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Ackermann, Mackay, and Arnold confirm, "Recent genomic research has shown that hybridization between substantially diverged lineages is the rule, not the exception, in human evolution." Acknowledging that there is still debate over how hybridization shaped human genotypes and phenotypes, the evolutionary biologists assert that hybridization was an essential creative force in the emergence of modern humans. In January 2019, scientists published a chronology for the Pleistocene deposits in the Denisova Cave concluding that at least two groups of humans, including Denisovans, Neanderthals, and related hybrids, occupied the Siberian site from around 300,000 to 20,000 years ago, but more material evidence is needed to prove whether they ever coexisted there. Material data collected at the site, including stone tools, bracelets, and other ornaments suggest that Denisovans may have been capable of higher order thought akin to modern humans. In February 2019, scientists discovered evidence, based on genetics studies using artificial intelligence (AI), that suggest the existence of an unknown human ancestor species, not Neanderthal, Denisovan or human hybrid (like Denny), in the genome of modern humans.
==== European football and further loans ==== For the first half of Tottenham's 2011–12 season, Townsend was a regular in their Europa League campaign, making six appearances in the competition. He scored his second goal for the club in their final match in the competition, against Shamrock Rovers on 15 December 2011, with a curled shot from outside the box. On 23 December, he signed a contract extension, making him a Tottenham player until the end of the 2016 season. With only one other appearance for Tottenham, in the League Cup, on 1 January 2012, Townsend joined Championship club Leeds United on loan until the end of the season, but with his agent claiming he was unhappy at the club, he switched the loan to their Championship rivals Birmingham City in February. For Leeds, he made seven appearances, including what he described as "a dream debut", and scored once. For Birmingham, he made fifteen league appearances and one in the second leg of their unsuccessful promotion play-off semi-final against Blackpool.
=== Polypeptides === The convention for a polypeptide is to list its constituent amino acid residues as they occur from the amino terminus to the carboxylic acid terminus. The amino acid residues are always joined by peptide bonds. Protein, though used colloquially to refer to any polypeptide, refers to larger or fully functional forms and can consist of several polypeptide chains as well as single chains. Proteins can also be modified to include non-peptide components, such as saccharide chains and lipids.
RTG technology was first developed by Los Alamos National Laboratory during the 1960s and 1970s to provide radioisotope thermoelectric generator power for cardiac pacemakers. Of the 250 plutonium-powered pacemakers Medtronic manufactured, twenty-two were still in service more than twenty-five years later, a feat that no battery-powered pacemaker could achieve. This same RTG power technology has been used in spacecraft such as Pioneer 10 and 11, Voyager 1 and 2, Cassini–Huygens and New Horizons, and in other devices, such as the Mars Science Laboratory and Mars 2020 Perseverance Rover, for long-term nuclear power generation.
Biologics can refer to a wide range of biological products in medicine. However, in most cases, the term is used more restrictively for a class of therapeutics (either approved or in development) that are produced using biological processes involving recombinant DNA technology. These medications are usually one of three types:
Sources: en.wikipedia.org
== Modern leather attire == Due to its high resistance to abrasion and wind, leather found a use in rugged occupations. The enduring image of a cowboy in leather chaps gave way to the leather-jacketed and leather-helmeted aviator. When motorcycles were invented, some riders took to wearing heavy leather jackets to protect from road rash and wind blast; some also wear chaps or full leather pants to protect the lower body. Leather's flexibility allows it to be formed and shaped into balls and protective gear. Subsequently, many sports use equipment made with leather, such as baseball gloves and the ball used in cricket and gridiron football. Leather fetishism is the name popularly used to describe a fetishistic attraction to people wearing leather, or in certain cases, to the garments themselves. Many rock groups (particularly heavy metal and punk groups in the 1970s and 80s) are well known for wearing leather clothing. Extreme metal bands (especially black metal bands) and Goth rock groups have extensive black leather clothing. Leather has become less common in the punk community over the last three decades, as there is opposition to the use of leather from punks who support animal rights. Many cars and trucks come with optional or standard leather or "leather faced" seating.
Poisoning can be either acute or chronic, and caused by a variety of natural or synthetic substances. Substances that destroy tissue but do not absorb, such as lye, are classified as corrosives rather than poisons.
=== Applications === The triple-stranded DNA regions can be generated through the association of Triplex Forming Oligonucleotides (TFO) and Peptide Nucleic Acids (PNAs). Historically, TFO binding has been shown to inhibit transcription, replication, and protein binding to DNA. TFOs tethered to mutagens have also been shown to promote DNA damage and induce mutagenesis. Although TFO have been known to hinder transcription and replication of DNA, recent studies have shown that TFO can be utilized to mediate site specific gene modifications both in vitro and in vivo. Another recent study has also shown that TFOs can be used for suppression of oncogenes and proto-oncogenes to reduce cancer cell growth. For example, a recent study has used TFOs to reduce cellular death in hepatoma cells through the decreasing the expression of MET. PNA TFOs have the ability to enhance recombination frequencies, leading to targeted, specific editing of genes. The PNA-DNA-PNA triplex helix is able to be recognized by the cell's own DNA repair mechanism, which sensitizes the surrounding DNA for homologous recombination. In order for a site-specific PNA structure to mediate recombination within a DNA sequence, a bis-PNA structure can be coupled with a 40nt DNA fragment that is homologous to an adjacent region on the target gene. The linking of a TFO to a donor DNA strand has been shown to induce recombination of the targeted gene and the adjacent gene target region.
== Epigenetics == The MTHFR aberrant promoter hypermethylation is associated with male infertility. Furthermore, this improper epigenetic phenomenon was observed in semen samples of infertile males belonging to couples with a history of recurrent spontaneous abortion. The MTHFR improper promoter hypermethylation may affect the two essential roles of DNA methylation in spermatogenetic cells, the global genome methylation process and the genomic imprinting of paternal genes. In addition, MTHFR gene promoter hypermethylation has also been associated with methylation loss at H19 imprinted gene in semen samples from infertile males.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.